#Clinical Research #ILIKOS Consulting #JCPR #Jordan #Amman

A New Era in Clinical Research in Jordan

In an impactful development for the pharmaceutical industry, ILIKOS Consulting Group has partnered with the Jordan Center for Pharmaceutical Research (JCPR) to enhance the landscape of bioequivalence (BE) and bioavailability (BA) studies in Jordan. This strategic partnership aims to leverage the advantages of conducting clinical research in this emerging region, ultimately supporting the global generics industry and improving patient access to new therapies.

The Partnership's Mission

The primary goal of the collaboration is to highlight the benefits of pursuing BE/BA clinical studies in Jordan for both local and international sponsors. As the pharmaceutical sector faces growing pressure from rising development costs and stringent regulatory requirements, the partnership represents a timely solution for overcoming these challenges.

Mr. Elias Sayias, Founder and CEO of ILIKOS, emphasizes the necessity of exploring innovative solutions within the generics sector, stating, "With increasing global pressures on the generics industry, from regulatory shifts to rising development costs, it's critical to explore innovative and reliable solutions. Jordan's strategic position, combined with JCPR's extensive expertise, offers a compelling value proposition for sponsors navigating the challenges of modern drug development."

Capabilities and Expertise of JCPR

Jordan Center for Pharmaceutical Research has established itself as a hub of excellence in clinical research with over two decades of experience. JCPR specializes in navigating complex regulatory environments, ensuring adherence to data standards, and providing reliable patient recruitment—key factors essential for successful clinical trials. As the first accredited Clinical Research Organization (CRO) in Amman, Jordan, JCPR holds multiple accreditations, including from the Jordan Food and Drug Administration (JFDA), the Gulf Cooperation Council (GCC), and the European Medicines Agency (EMA).

Eng. Tareq T. Arafat, Head of Business Development at JCPR, highlights the center's contributions, stating, "JCPR has been a cornerstone of clinical research excellence in the MENA region for over two decades. We are delighted to have expanded our footprint to Europe and strengthened our capabilities in areas like first-in-human studies and medical device testing."

Addressing Industry Challenges

The generics industry's landscape continues to evolve, presenting new challenges such as high competition, fluctuating development timelines, and complex data requirements. The collaboration between ILIKOS and JCPR is designed to tackle these challenges head-on by offering a comprehensive turnkey solution for generics manufacturers. This includes fast timelines for regulatory approvals and patient recruitment, which can greatly expedite the development process.

Advantages of Conducting Studies in Jordan

Jordan is becoming an increasingly attractive destination for conducting bioequivalence studies. The partnership will not only make use of JCPR's advanced infrastructure—which boasts over 120 beds across two state-of-the-art clinical sites—but will also take advantage of Jordan's capability to deliver fast timelines for approvals and start times for studies. Most notably, JCPR can achieve JFDA approval within two weeks of contract signing, with dosing commencing shortly after.

Through this partnership, ILIKOS and JCPR will work closely to ensure that local and international sponsors can navigate the complexities of modern drug development more efficiently. By bridging cultural, regulatory, and operational gaps, the partnership aims to deliver high-quality, cost-effective outcomes that benefit patients and researchers alike.

Conclusion

In a world where the efficacy and speed of therapeutic development are paramount, the strategic alliance between ILIKOS Consulting Group and the Jordan Center for Pharmaceutical Research marks a significant step forward. By focusing on high-quality clinical research and unparalleled support for generics manufactures, both organizations are poised to play a crucial role in the future of the pharmaceutical landscape in Jordan and beyond. Through their collaboration, they aim to facilitate better access to innovative therapies for patients and improve the overall standards of clinical research in the region.